Published in Circulation on April 15, 1995
JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart (2005) 9.79
Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. J Clin Invest (1996) 1.22
Statins for primary prevention: at what coronary risk is safety assured? Br J Clin Pharmacol (2001) 0.98
Efficacy of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for prevention of stroke. J Gen Intern Med (1999) 0.95
What an anticardiovascular diet should be in 2015. Curr Opin Lipidol (2015) 0.81
Economic valuation of the potential health benefits from foods enriched with plant sterols in Canada. Food Nutr Res (2010) 0.81
Fibrinogen and cardiovascular disease. J Clin Pathol (1997) 0.80
The impact of cholesterol lowering on patients' mood. J Behav Med (2001) 0.77
The characteristics of dyslipidemia patients with different durations in Beijing: a cross-sectional study. Lipids Health Dis (2010) 0.77
Depression in patients with heart disease: the case for more trials. Future Cardiol (2010) 0.77
Antihypertensive potential of combined extracts of olive leaf, green coffee bean and beetroot: a randomized, double-blind, placebo-controlled crossover trial. Nutrients (2014) 0.76
Association Between the Awareness of Dyslipidemia and Health Behavior for Control of Lipid Levels Among Korean Adults with Dyslipidemia. Korean J Fam Med (2017) 0.75
The one-stop coronary cholesterol clinic: a multidisciplinary approach to implementing evidence-based treatment. Postgrad Med J (1996) 0.75
Canadian Potential Healthcare and Societal Cost Savings from Consumption of Pulses: A Cost-Of-Illness Analysis. Nutrients (2017) 0.75
The Cardiovascular Health Study: design and rationale. Ann Epidemiol (1991) 27.24
Incidence of and risk factors for atrial fibrillation in older adults. Circulation (1997) 8.18
Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA (1997) 5.91
Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet (2000) 5.42
Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med (2000) 4.84
Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. Am J Hypertens (1996) 4.66
Health risks and benefits from calcium and vitamin D supplementation: Women's Health Initiative clinical trial and cohort study. Osteoporos Int (2012) 4.09
Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol (1994) 4.08
Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet (1996) 3.28
Time to act on drug safety. JAMA (1998) 3.22
Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med (1997) 3.05
The association of antihypertensive agents with MRI white matter findings and with Modified Mini-Mental State Examination in older adults. J Am Geriatr Soc (1997) 2.98
Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation (2000) 2.96
British guidelines on managing hypertension. Provide evidence, progress, and an occasional missed opportunity. BMJ (1999) 2.83
The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomized controlled trials. Prog Cardiovasc Dis (1987) 2.77
Depressive symptoms and risks of coronary heart disease and mortality in elderly Americans. Cardiovascular Health Study Collaborative Research Group. Circulation (2000) 2.71
Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc (1999) 2.71
Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke (2001) 2.65
Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med (2006) 2.55
Natural statins and stroke risk. Circulation (1999) 2.55
Thickening of the carotid wall. A marker for atherosclerosis in the elderly? Cardiovascular Health Study Collaborative Research Group. Stroke (1996) 2.48
Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation (1998) 2.47
Frequency and predictors of stroke death in 5,888 participants in the Cardiovascular Health Study. Neurology (2001) 2.41
Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet (2003) 2.37
Potential problems with random zero sphygmomanometer. Lancet (1990) 2.31
Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. BMJ (1989) 2.27
Antihypertensive drug therapies and the risk of ischemic stroke. Arch Intern Med (2001) 2.24
Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care (2000) 2.22
Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. JAMA (1999) 2.21
Isolated systolic hypertension and subclinical cardiovascular disease in the elderly. Initial findings from the Cardiovascular Health Study. JAMA (1992) 2.21
Treatment of hypertensive patients with diabetes. Lancet (1998) 2.16
Testing the statistical certainty of a response to increasing doses of a drug. Biometrics (1985) 2.14
Nimodipine neuroprotection in cardiac valve replacement: report of an early terminated trial. Stroke (1996) 2.10
Systolic Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design. Hypertension (1991) 2.04
Trends in pharmacologic management of hypertension in the United States. Arch Intern Med (1995) 2.04
Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: the cardiovascular health study. Arch Intern Med (2001) 2.01
Assessment of quality of life in clinical trials of cardiovascular therapies. Am J Cardiol (1984) 1.99
Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project. Eur Heart J (2002) 1.98
Surgical bleeding: unexpected effect of a calcium antagonist. BMJ (1995) 1.88
Beta-adrenergic blockade for survivors of acute myocardial infarction. N Engl J Med (1984) 1.82
Change in cholesterol awareness and action. Results from national physician and public surveys. Arch Intern Med (1991) 1.75
Cardiovascular disease in older adults with glucose disorders: comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria. Lancet (1999) 1.73
Secondary prevention after myocardial infarction: a review of long-term trials. Prog Cardiovasc Dis (1982) 1.71
Cognitive function and retinal and ischemic brain changes: the Women's Health Initiative. Neurology (2012) 1.68
Treatment of isolated systolic hypertension is most effective in older patients with high-risk profile. Circulation (2001) 1.68
Lessons learned from a prospective meta-analysis. J Am Geriatr Soc (1995) 1.65
Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA (1993) 1.60
Effect of vasodilators on survival in chronic congestive heart failure. Am J Cardiol (1985) 1.60
Developing an optimal approach to global drug safety. J Intern Med (2001) 1.57
Renal insufficiency and cardiovascular events in postmenopausal women with coronary heart disease. J Am Coll Cardiol (2001) 1.56
Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events. Lancet (1997) 1.56
Quality of life with three antihypertensive treatments. Cilazapril, atenolol, nifedipine. Hypertension (1992) 1.53
Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation (2000) 1.51
Use of calcium channel blockers and breast carcinoma risk in postmenopausal women. Cancer (1997) 1.50
Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association. Circulation (2001) 1.48
Postmenopausal hormone therapy for disease prevention: have we learned any lessons from the past? Clin Pharmacol Ther (2008) 1.45
Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II) Am J Cardiol (1995) 1.43
Traditional risk factors and subclinical disease measures as predictors of first myocardial infarction in older adults: the Cardiovascular Health Study. Arch Intern Med (1999) 1.39
Effect of propranolol in postinfarction patients with mechanical or electrical complications. Circulation (1984) 1.38
[Calcium antagonists: safe or unsafe?]. Ned Tijdschr Geneeskd (1996) 1.38
Utility of new electrocardiographic models for left ventricular mass in older adults. The Cardiovascular Health Study Collaborative Research Group. Hypertension (1996) 1.37
HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data. Atherosclerosis (1998) 1.37
Oral anticoagulation in patients with atrial fibrillation: adherence with guidelines in an elderly cohort. Am J Med (1999) 1.33
Time trends in the use of cholesterol-lowering agents in older adults: the Cardiovascular Health Study. Arch Intern Med (1998) 1.24
Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. Asymptomatic Carotid Artery Progression Study Research Group. Stroke (1996) 1.19
Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. Am J Cardiol (1985) 1.19
Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) pilot study. Stroke (1989) 1.17
Risk factors for hospitalized gastrointestinal bleeding among older persons. Cardiovascular Health Study Investigators. J Am Geriatr Soc (2001) 1.17
HMG CoA reductase inhibitors and quality of life. JAMA (1993) 1.16
Reduction in burden of illness: a new efficacy measure for prevention trials. Stat Med (1994) 1.14
Drop-out and newcomer bias in a community cardiovascular follow-up study. Int J Epidemiol (1990) 1.13
Temporal trends in the use of anticoagulants among older adults with atrial fibrillation. Arch Intern Med (1999) 1.12
Usefulness of T-axis deviation as an independent risk indicator for incident cardiac events in older men and women free from coronary heart disease (the Cardiovascular Health Study). Am J Cardiol (2001) 1.09
Coronary risk factor screening in three rural communities. The CORIS baseline study. S Afr Med J (1983) 1.08
Digoxin Immune Fab therapy in the management of digitalis intoxication: safety and efficacy results of an observational surveillance study. J Am Coll Cardiol (1991) 1.08
The evolution of the Women's Health Initiative: perspectives from the NIH. J Am Med Womens Assoc (1995) 1.07
Reliable evidence from placebo-controlled, randomized, clinical trials for menopausal hormone therapy's influence on incidence and deaths from breast cancer. Climacteric (2015) 1.07
Age as a predictor of outcome: what role does it play? Am J Med (1992) 1.06
Effect of long-term prophylactic treatment on survival after myocardial infarction. Am J Med (1984) 1.05
Relation between blood lipids, lipoproteins, and cerebrovascular atherosclerosis. A review. Stroke (1988) 1.04
Does antihypertensive treatment of the elderly prevent cardiovascular events or prolong life? A meta-analysis of hypertension treatment trials. Arch Fam Med (1995) 1.03
Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation (1995) 1.03
Cost-minimization and the number needed to treat in uncomplicated hypertension. Am J Hypertens (1998) 1.02
Hypertension, heart rate, use of antihypertensives, and incident prostate cancer. Ann Epidemiol (2001) 1.01
Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol (1996) 1.01
Corrections to the nifedipine meta-analysis. Circulation (1996) 0.99
The intervention effects of a community-based hypertension control programme in two rural South African towns: the CORIS Study. S Afr Med J (1993) 0.98
Isoprostane 8-epi-PGF2alpha is frequently increased in patients with muscle pain and/or CK-elevation after HMG-Co-enzyme-A-reductase inhibitor therapy. J Clin Pharm Ther (2001) 0.98
The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia. Prostate (1993) 0.97
Cardiac arrhythmias on 24-h ambulatory electrocardiography in older women and men: the Cardiovascular Health Study. J Am Coll Cardiol (1994) 0.97
Surrogates, semantics, and sensible public policy. Circulation (1997) 0.96
Prognostic value of exercise electrocardiogram in men at high risk of future coronary heart disease: Multiple Risk Factor Intervention Trial experience. J Am Coll Cardiol (1986) 0.96
Low or lowered cholesterol and risk of death from suicide and trauma. Metabolism (1993) 0.96
Reproducibility of noninvasive ultrasonic measurement of carotid atherosclerosis. The Asymptomatic Carotid Artery Plaque Study. Stroke (1992) 0.96
Secondary prevention after myocardial infarction: a review of short-term acute phase trials. Prog Cardiovasc Dis (1983) 0.95
Relationship of blood pressure to coronary and stroke morbidity and mortality in clinical trials and epidemiological studies. J Hypertens Suppl (1986) 0.94